Synchronized chemoradiotherapy (CRT) is currently the standard of care for patients with limited advanced lung adenocarcinoma, but the effect of EGFR mutation status on CRT has been rarely reported. A study conducted by Japanese authors Tanaka, Kosuke aimed to investigate the effect of EGFR mutation status on radical CRT for inoperable stage III lung adenocarcinoma. (Journal of Thoracic Oncology. 2015,10(12): 1720C1725) Between 2006 and 2013, 104 patients with inoperable stage III lung adenocarcinoma with definite EGFR mutation status who received radical CRT (platinum-containing two-drug chemotherapy) in the first line were included in the study by retrospective analysis, and patients were compared according to their The study included 104 patients with inoperable stage III lung adenocarcinoma who received first-line radical CRT (platinum-containing two-drug chemotherapy) with definite EGFR mutation status. Among the 104 patients enrolled, 29 patients (28%) were found to be EGFR mutation positive. No significant differences were seen in objective remission rates between the two groups (EGFR mutation group vs. EGFR wild group) (72.4% vs. 72.0%, P=0.607), and the median PFS was shorter for EGFR mutation than for wild type receiving CRT (9.8 months vs. 16.5 months, 95% CI: (7.6-19.0) vs. (11.8-19.9), P=0.041 ), lower 2-year recurrence-free survival (7.7% vs. 28.1%, P=0.028), local recurrence was less common (14% vs. 35%, P=0.027), and distant metastases were more common as the first recurrent lesion (76% vs. 40%, P=0.001), with brain metastases being the most common (35%). Overall survival was similar in both groups (51.1 months vs 42.9 months, 95% CI: (28.2-70.2) vs (35.3- NA), P=0.637). For EGFR wild-type patients, overall survival was shorter for Kras mutant than wild-type patients (21.6 months vs 49.8 months, P=0.024). The study concluded that patients with EGFR mutant stage III lung adenocarcinoma treated with simultaneous CRT had better local tumor control but shorter PFS compared with EGFR wild-type patients, which was mainly attributed to a greater susceptibility to distant metastases. Such biological characteristics make it possible that in patients with EGFR mutant locally advanced lung adenocarcinoma, radical CRT may need to be combined with EGFR-TKI therapy.